| Gennari, Alessandra |
NCT04460807: Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer |
|
|
| Terminated | 3 | 23 | Europe | Exemestane, Mestane, Placebo oral tablet | Ente Ospedaliero Ospedali Galliera, Istituto Di Ricerche Farmacologiche Mario Negri, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Federation of Italian Cooperative Oncology Groups | Ovarian Cancer | 04/23 | 04/23 | | |
| Recruiting | 3 | 400 | Europe | Palbociclib 125mg, Ibrance, PD-0332991, Standard endocrine therapy | ETOP IBCSG Partners Foundation, Pfizer | Breast Cancer Recurrent | 12/24 | 11/26 | | |
| Recruiting | 3 | 700 | Europe | Oxaliplatin, Capecitabine, Folinic acid, Fluorouracil, Temozolomide, Irinotecan, Nivolumab, Ipilimumab, Trastuzumab, Pertuzumab, Panitumumab | IFOM ETS - The AIRC Institute of Molecular Oncology | Colon Cancer Stage II, Colon Cancer Stage III | 03/26 | 09/28 | | |
| Active, not recruiting | 3 | 1332 | Europe | Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy | German Breast Group, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER | HER2-negative Breast Cancer, Triple Negative Breast Cancer | 03/27 | 03/29 | | |
| Completed | 2 | 258 | Europe | nab-Paclitaxel, Abraxane | ETOP IBCSG Partners Foundation, Breast International Group | Metastatic Breastcancer | 05/16 | 03/23 | | |
ATRiBRAVE, NCT05582538: Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel |
|
|
| Recruiting | 2 | 37 | Europe | Ceralasertib, AZD6738, Durvalumab, IMFINZI, Nab-paclitaxel, ABRAXANE, PAZENIR | IFOM ETS - The AIRC Institute of Molecular Oncology, AstraZeneca | Triple Negative Breast Cancer Metastatic | 05/25 | 11/25 | | |
PREcoopERA, NCT05896566: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer |
|
|
| Recruiting | 2 | 220 | Europe | Giredestrant, Triptorelin, Anastrozole | ETOP IBCSG Partners Foundation, Hoffmann-La Roche | Breast Cancer | 06/26 | 06/26 | | |
| Recruiting | N/A | 144 | Europe | | Lorenza Scotti | Hematologic Malignancies, Solid Tumor, Elderly Patients | 09/21 | 05/22 | | |
NCT05754502: Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy |
|
|
| Recruiting | N/A | 300 | Europe | Trastuzumab emtansine | Consorzio Oncotech, Roche Pharma AG | Breast Cancer | 09/24 | 05/25 | | |
